Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Abstract Background Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection versus EPO for treating renal anemia...

Full description

Bibliographic Details
Main Authors: Shubhadeep D. Sinha, Vamsi Krishna Bandi, Bala Reddy Bheemareddy, Pankaj Thakur, Sreenivasa Chary, Kalpana Mehta, Vikranth Reddy Pinnamareddy, Rajendra Pandey, Subhramanyam Sreepada, Santosh Durugkar
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Nephrology
Subjects:
Darbepoetin alfa
Erythropoietin
Anemia
Dialysis
End-stage renal disease
Online Access:http://link.springer.com/article/10.1186/s12882-019-1209-1

Internet

http://link.springer.com/article/10.1186/s12882-019-1209-1

Similar Items